Personalized drug attack on breast cancer before surgery
NCT ID NCT05101564
Summary
This study tested if adding a new drug targeted to a tumor's specific genetic changes before surgery could slow cancer growth better than standard hormone therapy alone. It involved 19 people with a common type of breast cancer (ER-positive, HER2-negative). The goal was to see if the personalized approach was more effective at reducing a marker of cancer cell growth (Ki67) after just two weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
Explore the condition pages connected to this study.